
Page#1
AMGEN INC.
CONSOLIDATED STATEMENTS OF INCOME
Years ended December 31, 2015, 2014 and 2013
(In millions, except per share data)
 
2015 2014 2013
Revenues: 
Product sales $ 20,944  $ 19,327  $ 18,192
Other revenues 718  736  484
Total revenues 21,662  20,063  18,676
 
Operating expenses: 
Cost of sales 4,227  4,422  3,346
Research and development 4,070  4,297  4,083
Selling, general and administrative 4,846  4,699  5,184
Other 49  454  196
Total operating expenses 13,192  13,872  12,809
 
Operating income 8,470  6,191  5,867
 
Interest expense, net 1,095  1,071  1,022
Interest and other income, net 603  465  420
 
Income before income taxes 7,978  5,585  5,265
 
Provision for income taxes 1,039  427  184
 
Net income $ 6,939  $ 5,158  $ 5,081
 
Earnings per share: 
Basic $ 9.15  $ 6.80  $ 6.75
Diluted $ 9.06  $ 6.70  $ 6.64
 
Shares used in the calculation of earnings per share: 
Basic 758  759  753
Diluted 766  770  765
See accompanying notes.
F-2
Page#2
AMGEN INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Years ended December 31, 2015, 2014 and 2013
(In millions)
 
2015 2014 2013
Net income $ 6,939  $ 5,158  $ 5,081
Other comprehensive (loss) income, net of reclassification adjustments and taxes:  
Foreign currency translation losses (247)  (196)  (80)
Effective portion of cash flow hedges 7  323  2
Net unrealized (losses) gains on available-for-sale securities (241)  24  (226)
Other 9  2  (3)
Other comprehensive (loss) income, net of tax (472)  153  (307)
Comprehensive income $ 6,467  $ 5,311  $ 4,774
See accompanying notes.
F-3
Page#3
AMGEN INC.
CONSOLIDATED BALANCE SHEETS
December 31, 2015 and 2014
(In millions, except per share data)
  
2015 2014
ASSETS
Current assets: 
Cash and cash equivalents $ 4,144  $ 3,731
Marketable securities 27,238  23,295
Trade receivables, net 2,995  2,546
Inventories 2,435  2,647
Other current assets 1,706  2,494
Total current assets 38,518  34,713
 
Property, plant and equipment, net 4,907  5,223
Intangible assets, net 11,641  12,693
Goodwill 14,787  14,788
Other assets 1,723  1,592
Total assets $ 71,576  $ 69,009
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities: 
Accounts payable $ 965  $ 995
Accrued liabilities 5,452  5,513
Current portion of long-term debt 2,250  500
Total current liabilities 8,667  7,008
 
Long-term debt 29,306  30,215
Long-term deferred tax liability 2,239  3,461
Other noncurrent liabilities 3,281  2,547
 
Contingencies and commitments 
 
Stockholders’ equity: 
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding
— 754.0 shares in 2015 and 760.4 shares in 2014 30,649  30,410
Accumulated deficit (2,086)  (4,624)
Accumulated other comprehensive loss (480)  (8)
Total stockholders’ equity 28,083  25,778
Total liabilities and stockholders’ equity $ 71,576  $ 69,009
See accompanying notes.
F-4
Page#4
AMGEN INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years ended December 31, 2015, 2014 and 2013
(In millions)
 
2015 2014 2013
Cash flows from operating activities: 
Net income $ 6,939  $ 5,158  $ 5,081
Depreciation and amortization 2,108  2,092  1,286
Stock-based compensation expense 322  408  403
Deferred income taxes (607)  (108)  (189)
Other items, net (399)  (116)  103
Changes in operating assets and liabilities, net of acquisitions:  
Trade receivables, net (420)  136  (38)
Inventories 481  327  (7)
Other assets 155  (1)  (59)
Accounts payable (12)  228  60
Accrued income taxes 509  (103)  (326)
Other liabilities 1  534  (23)
Net cash provided by operating activities 9,077  8,555  6,291
Cash flows from investing activities: 
Purchases of property, plant and equipment (594)  (718)  (693)
Cash paid for acquisitions, net of cash acquired (359)  (165)  (9,434)
Purchases of intangible assets (55)  (285)  —
Purchases of marketable securities (25,977)  (25,878)  (21,965)
Proceeds from sales of marketable securities 18,029  16,697  19,123
Proceeds from maturities of marketable securities 3,527  4,199  5,090
Proceeds from sale of property, plant and equipment 274  3  20
Change in restricted investments, net —  533  (520)
Other (392)  (138)  (90)
Net cash used in investing activities (5,547)  (5,752)  (8,469)
Cash flows from financing activities: 
Net proceeds from issuance of debt 3,465  4,476  8,054
Repayment of debt (2,400)  (5,605)  (3,371)
Repurchases of common stock (1,867)  (138)  (832)
Dividends paid (2,396)  (1,851)  (1,415)
Net proceeds from issuance of common stock in connection with the Company’s
equity award programs 82  186  296
Settlement of contingent consideration obligations (253)  (92)  —
Other 252  147  (6)
Net cash (used in) provided by financing activities (3,117)  (2,877)  2,726
Increase (decrease) in cash and cash equivalents 413  (74)  548
Cash and cash equivalents at beginning of period 3,731  3,805  3,257
Cash and cash equivalents at end of period $ 4,144  $ 3,731  $ 3,805
See accompanying notes.
F-6